Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre, Eastern Ethiopia.
Ethiopia
Glucose-6-phosphate dehydrogenase
Metehara
Plasmodium falciparum
Plasmodium vivax
Primaquine
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
08 Sep 2022
08 Sep 2022
Historique:
received:
11
01
2022
accepted:
17
08
2022
entrez:
8
9
2022
pubmed:
9
9
2022
medline:
14
9
2022
Statut:
epublish
Résumé
Glucose-6-phosphate dehydrogenase (G6PD) is cytosolic enzyme, which has a vital role for the integrity and functioning of red blood cells. Lower activity of this enzyme leads to the occurrence of acute haemolytic anaemia after exposure to oxidative stressors like primaquine. Primaquine is an important drug for the radical cure of Plasmodium vivax and blocking transmission of Plasmodium falciparum, and thereby enhancing malaria elimination. However, there is a need to identify G6PD deficient individuals and administer the drug with caution due to its haemolytic side effects. The main objective of this study is to determine the prevalence of G6PD deficiency among malaria-suspected individuals. A facility-based cross-sectional study was conducted from September 2020 to September 2021 in Metehara Health Centre, Eastern Ethiopia. A structured questionnaire was used to collect the socio-demographic and clinical information of the study participants. Capillary and venous blood samples were collected based on standard procedures for onsite screening, dried blood spot preparation, and malaria microscopy. The G6PD enzyme activity was measured by careSTART™ G6PD biosensor analyzer. Data was entered and analysed by SPSS. A total of 498 study participants were included in the study, of which 62% (309) were males. The overall prevalence of G6PD deficiency based on the biosensor screening was 3.6% (18/498), of which 2.9% and 4.8% were males and females, respectively. Eleven of the G6PD deficient samples had mutations confirmed by G6PD gene sequencing analysis. Mutations were detected in G267 + 119C/T, A376T, and ChrX:154535443. A significant association was found in sex and history of previous malaria infection with G6PD deficiency. The study showed that the G6PD deficient phenotype exists in Metehara even if the prevalence is not very high. G267 + 119C/T mutation is the predominant G6PD variant in this area. Therefore, malaria patient treatment using primaquine should be monitored closely for any adverse effects.
Sections du résumé
BACKGROUND
BACKGROUND
Glucose-6-phosphate dehydrogenase (G6PD) is cytosolic enzyme, which has a vital role for the integrity and functioning of red blood cells. Lower activity of this enzyme leads to the occurrence of acute haemolytic anaemia after exposure to oxidative stressors like primaquine. Primaquine is an important drug for the radical cure of Plasmodium vivax and blocking transmission of Plasmodium falciparum, and thereby enhancing malaria elimination. However, there is a need to identify G6PD deficient individuals and administer the drug with caution due to its haemolytic side effects. The main objective of this study is to determine the prevalence of G6PD deficiency among malaria-suspected individuals.
METHODS
METHODS
A facility-based cross-sectional study was conducted from September 2020 to September 2021 in Metehara Health Centre, Eastern Ethiopia. A structured questionnaire was used to collect the socio-demographic and clinical information of the study participants. Capillary and venous blood samples were collected based on standard procedures for onsite screening, dried blood spot preparation, and malaria microscopy. The G6PD enzyme activity was measured by careSTART™ G6PD biosensor analyzer. Data was entered and analysed by SPSS.
RESULTS
RESULTS
A total of 498 study participants were included in the study, of which 62% (309) were males. The overall prevalence of G6PD deficiency based on the biosensor screening was 3.6% (18/498), of which 2.9% and 4.8% were males and females, respectively. Eleven of the G6PD deficient samples had mutations confirmed by G6PD gene sequencing analysis. Mutations were detected in G267 + 119C/T, A376T, and ChrX:154535443. A significant association was found in sex and history of previous malaria infection with G6PD deficiency.
CONCLUSIONS
CONCLUSIONS
The study showed that the G6PD deficient phenotype exists in Metehara even if the prevalence is not very high. G267 + 119C/T mutation is the predominant G6PD variant in this area. Therefore, malaria patient treatment using primaquine should be monitored closely for any adverse effects.
Identifiants
pubmed: 36076204
doi: 10.1186/s12936-022-04269-5
pii: 10.1186/s12936-022-04269-5
pmc: PMC9461287
doi:
Substances chimiques
Antimalarials
0
Primaquine
MVR3634GX1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
260Subventions
Organisme : NIAID NIH HHS
ID : R01 AI162947
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Malar J. 2018 Oct 26;17(1):388
pubmed: 30367627
Malar J. 2014 Nov 18;13:438
pubmed: 25406667
Blood Cells Mol Dis. 2009 May-Jun;42(3):267-78
pubmed: 19233695
PLoS One. 2017 Feb 2;12(2):e0171208
pubmed: 28152025
PLoS One. 2017 Jan 25;12(1):e0169930
pubmed: 28121993
Wellcome Open Res. 2018 Jan 2;3:1
pubmed: 29552643
Mediterr J Hematol Infect Dis. 2016 Jun 15;8(1):e2016029
pubmed: 27413522
PLoS One. 2015 Jul 30;10(7):e0134593
pubmed: 26226515
Front Cell Infect Microbiol. 2021 Sep 03;11:696598
pubmed: 34540716
PLoS Negl Trop Dis. 2021 Aug 12;15(8):e0009649
pubmed: 34383774
Am J Trop Med Hyg. 2018 Jan;98(1):83-87
pubmed: 29141760
Vox Sang. 2013 Nov;105(4):271-82
pubmed: 23815264
Malar J. 2016 Jul 07;15(1):346
pubmed: 27388012
BMJ Glob Health. 2021 Feb;6(2):
pubmed: 33619041
Infect Dis Poverty. 2021 Aug 5;10(1):105
pubmed: 34353361
PLoS One. 2016 Apr 29;11(4):e0154618
pubmed: 27128799
Malar J. 2017 Jan 19;16(1):36
pubmed: 28103889
PLoS Med. 2015 Oct 27;12(10):e1001891
pubmed: 26505753
Malar J. 2018 Oct 12;17(1):358
pubmed: 30314477
Malar J. 2019 Feb 28;18(1):57
pubmed: 30819192
Cardiovasc Hematol Disord Drug Targets. 2013 Mar 1;13(1):73-82
pubmed: 23534950
Malar J. 2018 Aug 2;17(1):281
pubmed: 30071859
PLoS One. 2019 Dec 20;14(12):e0226927
pubmed: 31860695
PLoS One. 2021 Sep 27;16(9):e0257562
pubmed: 34570821
Malar J. 2016 May 26;15(1):291
pubmed: 27225440
BMC Infect Dis. 2018 Mar 16;18(1):131
pubmed: 29548282
Infect Dis Poverty. 2021 Aug 23;10(1):113
pubmed: 34425898
Malar J. 2017 Sep 11;16(1):361
pubmed: 28893237
Lancet. 2008 Jan 5;371(9606):64-74
pubmed: 18177777
Malar J. 2017 May 23;16(1):214
pubmed: 28535765
Bull World Health Organ. 1989;67(6):601-11
pubmed: 2633878
Tex Heart Inst J. 2018 Jun 1;45(3):144-150
pubmed: 30072850
Methods Mol Biol. 2017;1560:3-13
pubmed: 28155142
Malar J. 2019 Oct 7;18(1):340
pubmed: 31590661
Am J Trop Med Hyg. 2017 Oct;97(4):1262-1270
pubmed: 28820691
Acta Trop. 2020 Feb;202:105252
pubmed: 31678235
Int J Mol Sci. 2016 Dec 09;17(12):
pubmed: 27941691
PLoS One. 2018 Nov 2;13(11):e0206331
pubmed: 30388146
Trends Parasitol. 2011 Jan;27(1):11-6
pubmed: 20846906
Pan Afr Med J. 2018 Sep 20;31:46
pubmed: 30918572